ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
5 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
123
|
21K
|
5
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
6 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
123
|
21K
|
6
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNBV MoU Webinar presentation
|
|
Beno77
|
88 |
14K |
0 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
88
|
14K
|
0
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNBV MoU Webinar presentation
|
|
Beno77
|
88 |
14K |
1 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
88
|
14K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNBV MoU Webinar presentation
|
|
Beno77
|
88 |
14K |
2 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
88
|
14K
|
2
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNBV MoU Webinar presentation
|
|
Beno77
|
88 |
14K |
4 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
88
|
14K
|
4
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNBV MoU Webinar presentation
|
|
Beno77
|
88 |
14K |
6 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
88
|
14K
|
6
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNBV MoU Webinar presentation
|
|
Beno77
|
88 |
14K |
10 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
88
|
14K
|
10
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
9 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
123
|
21K
|
9
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
6 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
123
|
21K
|
6
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
6 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
123
|
21K
|
6
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
1 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
123
|
21K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
6 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
123
|
21K
|
6
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
5 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
123
|
21K
|
5
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
9 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
123
|
21K
|
9
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
4 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
123
|
21K
|
4
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
6 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
123
|
21K
|
6
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
7 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
123
|
21K
|
7
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
5 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
123
|
21K
|
5
|
|
ASX - By Stock
|
1AD |
Re:
Ann: SYNThesis BioVentures MoU for cellular immunotherapies
|
|
Beno77
|
123 |
21K |
9 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
123
|
21K
|
9
|
|
Commodities
|
GOLD |
Re:
gold
|
|
Beno77
|
126K |
48M |
1 |
06/04/24 |
06/04/24 |
Commodities
|
126K
|
48M
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
2 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
262
|
47K
|
2
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
3 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
262
|
47K
|
3
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
4 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
262
|
47K
|
4
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
5 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
262
|
47K
|
5
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
9 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
262
|
47K
|
9
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
4 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
262
|
47K
|
4
|
|
ASX - By Stock
|
1AD |
Re:
Ann: January 2024 partnering presentations and progress
|
|
Beno77
|
22 |
5.2K |
5 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
22
|
5.2K
|
5
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
3 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
262
|
47K
|
3
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
3 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
262
|
47K
|
3
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
3 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
262
|
47K
|
3
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
1 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
262
|
47K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
4 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
262
|
47K
|
4
|
|
Commodities
|
GOLD |
Re:
gold
|
|
Beno77
|
126K |
48M |
0 |
04/04/24 |
04/04/24 |
Commodities
|
126K
|
48M
|
0
|
|
Commodities
|
GOLD |
Re:
gold
|
|
Beno77
|
126K |
48M |
4 |
04/04/24 |
04/04/24 |
Commodities
|
126K
|
48M
|
4
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
5 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
262
|
47K
|
5
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
1 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
262
|
47K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
4 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
262
|
47K
|
4
|
|
ASX - By Stock
|
1AD |
Re:
Ann: 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer
|
|
Beno77
|
10 |
3.2K |
1 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
10
|
3.2K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
9 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
262
|
47K
|
9
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
1 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
262
|
47K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
2 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
262
|
47K
|
2
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
0 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
262
|
47K
|
0
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
1 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
262
|
47K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
4 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
262
|
47K
|
4
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
6 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
262
|
47K
|
6
|
|
ASX - By Stock
|
BEZ |
Re:
Ann: Trading Halt
|
|
Beno77
|
97 |
21K |
2 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
97
|
21K
|
2
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
0 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
262
|
47K
|
0
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
0 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
262
|
47K
|
0
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Positive AD-214 Phase I extension study results
|
|
Beno77
|
262 |
47K |
1 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
262
|
47K
|
1
|
|